Friday, September 30, 2022


Biotechnology News Magazine

Cytovia Therapeutics Presents Antitumor Activity of its CD38-Targeting Flex-NK™ Cell Engager Antibody at EHA 2022 Congress

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the European Hematology Association’s annual congress in Vienna, Austria on June 10th, 2022 is now available on both the EHA and Cytovia websites.

For details on in-person poster presentations, please see the following:

Session Title: Poster session
Session date and time: Friday, June 10 2022 – 16:30 – 17:45 CEST
Final Abstract Code: P842
Abstract Link:

Summary: CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activating receptor NKp46. CYT-338 pharmacokinetics and pharmacodynamics was studied using in vitro and in vivo multiple myeloma models. CYT-338 showed 3-fold higher dose-dependent binding to CD38 expressing MM cell lines compared to daratumumab. Epitope mapping studies indicated that CYT-338 binds to a different CD38 epitope compared to daratumumab. CYT-338 showed greater dose dependent NK cell redirected cytolysis, degranulation, and cytokine production against MM1S cells compared to daratumumab. CYT-338 showed minimal immune subset depletion, NK cell fratricide, and cytokine release compared to daratumumab in vitro. CYT-338 showed tumor growth inhibition and improved survival in in vivo models of multiple myeloma. These results support further development of CYT-338 as a therapeutic for targeting CD38 expressing multiple myeloma cells distinct from daratumumab.

About CD38
Cluster of differentiation 38 (CD38) is a type II receptor membrane glycoprotein that plays a role in cell adhesion, migration, and signal transduction. Additionally, CD38 is an ectoenzyme involved in generation of nucleotide metabolites, such as ADP-Ribose that regulate cell metabolism. CD38 is highly expressed in multiple myeloma (MM) on malignant plasma cells and is also moderately expressed on normal T, B, NK and myeloid cells. Antibodies targeting CD38, such as daratumumab and isatuximab, are FDA approved for the treatment of MM as monotherapy and in combination.


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine